v3.26.3
Exclusive License and Option Agreement with Roche (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 29, 2026
USD ($)
obligation
Nov. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Convertible note, at fair value             $ 41,600
Other long-term liabilities     $ 1,515   $ 1,515   15,433
Number of performance obligations | obligation 2            
Accounts receivable     8,821   8,821   1,307
Research and development     68,417 $ 50,627 174,804 $ 145,486  
Deferred revenue, non-current, related party     24,594   24,594   49,138
Deferred revenue, current     $ 0   $ 0   7,123
Roche Holdings              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Ownership interest     17.00%   17.00%    
Related Party              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Other long-term liabilities     $ 1,140   $ 1,140    
Accounts receivable     8,000   8,000    
Deferred revenue, non-current, related party     24,594   24,594    
Convertible Debt | Roche Convertible Note              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate principal amount   $ 75,000          
Convertible note, at fair value   $ 60,000          
Roche License and Option Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Evaluation period   2 years          
Option exercise fee   $ 10,000          
Option exercise fee payment period   30 days          
Milestone payments receivable   $ 100,000          
Roche License and Option Agreement | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price $ 35,000   34,900   34,900    
Residual Proceeds | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price 15,000            
Fixed and Variable Consideration | Milestone #1 | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price 20,000            
Noncash Consideration | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price $ 4,000            
SBX Evaluation | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price     10,300   10,300    
Performance obligation amount     $ 35,000   $ 35,000    
SBX Evaluation | License and collaboration revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-09-30              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Performance obligation period 24 months            
SBX Evaluation | License and collaboration revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Performance obligation period     24 months   24 months    
SBX Evaluation | Milestone #2 | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price     $ 8,000   $ 8,000    
Material Right | License and collaboration revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Transaction price     24,600   24,600    
Roche License and Option Agreement and Roche Promissory Note Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Proceeds from related party transaction   $ 75,000          
Roche License and Option Agreement | Related Party              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Other long-term liabilities     15,000   15,000   $ 15,000
Accounts receivable $ 8,000            
Research and development $ 3,400            
Deferred revenue, non-current, related party     24,600   24,600    
Deferred revenue, current     1,200   1,200    
SBX Evaluation | Related Party              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Other long-term liabilities     1,100   1,100    
Transaction price     2,300   2,300    
Deferred revenue, current     $ 1,200   $ 1,200